Role of HLA in transplant

Introduction and Genetic Basis

Human Leukocyte Antigens (HLA) are cell-surface glycoproteins encoded by the Major Histocompatibility Complex (MHC) gene cluster located on the short arm of chromosome $6$ ($6\text{p}21.3$). HLA molecules exhibit extreme polymorphism and play a fundamental role in transplant immunology, acting as the primary alloantigens that trigger host immune responses.

Classification of HLA Molecules

HLA molecules are divided into two primary functional classes:

• Class I ($\text{HLA-A}$, $\text{HLA-B}$, $\text{HLA-C}$):
  • Expression: Present on all nucleated cells and platelets.
  • Function: Present endogenous antigens to ${\text{CD8}}^{+}$ cytotoxic T-lymphocytes.
  • Structure: Heterodimer composed of an $\alpha$ heavy chain (polymorphic) non-covalently associated with ${\beta }_2$-microglobulin (encoded on chromosome $15$).
• Class II ($\text{HLA-DR}$, $\text{HLA-DQ}$, $\text{HLA-DP}$):
  • Expression: Restituted to antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B-cells (can be induced on vascular endothelial cells during inflammation).
  • Function: Present exogenous antigens to ${\text{CD4}}^{+}$ helper T-lymphocytes
  • Structure: Heterodimer of $\alpha$ and $\beta$ chains (both polymorphic).

Mechanisms of HLA-Mediated Allorecognition

When a graft is transplanted, the recipient's T-cells recognize foreign HLA antigens via two primary pathways:

• Direct Pathway: Recipient T-cells directly recognize intact, foreign HLA molecules expressed on donor-derived APCs (passenger leukocytes) within the graft. This pathway is highly potent and drives acute cellular rejection.
• Indirect Pathway: Recipient APCs process shed donor HLA proteins and present donor-derived HLA peptide fragments on self-MHC molecules to recipient T-cells. This pathway plays a dominant role in chronic rejection and antibody-mediated rejection (AMR).

Role of HLA Matching in Different Transplants

HLA compatibility requirements vary significantly depending on the organ or tissue transplanted:

1. Solid Organ Transplantation (e.g., Kidney)

• Target Matches: Primarily focuses on matching $\text{HLA-A}$, $\text{HLA-B}$, and $\text{HLA-DR}$ (often referred to as a "6-antigen match").
• Impact: Minimizing HLA mismatches directly correlates with reduced rates of acute rejection, improved long-term graft survival, and decreased requirement for high-dose maintenance immunosuppression.
• Sensitization: Mismatches predispose the recipient to developing anti-donor HLA antibodies, making re-transplantation extremely difficult.

2. Hematopoietic Stem Cell Transplantation (HSCT)

• Target Matches: Demands high-resolution (allele-level) molecular matching.
• High-Resolution Match: Standard of care requires an $8/8$ match ($\text{HLA-A, -B, -C, -DRB1}$) or $10/10$ match (including $\text{HLA-DQB1}$).
• Clinical Implications:
  • Graft-versus-Host Disease (GvHD): Mediated by donor T-cells recognizing host HLA mismatches. Mismatches at $\text{HLA-C}$ and $\text{HLA-DP}$ are strongly linked to acute GvHD.
  • Graft Rejection: Host T-cells/NK-cells rejecting donor stem cells.
  • Graft-versus-Leukemia (GvL) Effect: Controlled HLA mismatches can sometimes be exploited to enhance GvL while managing GvHD.

Immunology Testing and Crossmatching

To ensure histocompatibility, pediatric transplant programs utilize a sequential testing algorithm:

1. HLA Typing

• Serological Typing (Historical): Uses microlymphocytotoxicity assays (limited resolution).
• Molecular Typing (Current Standard):
  • PCR-SSP (Sequence-Specific Primers) and PCR-SSOP (Sequence-Specific Oligonucleotide Probes) for intermediate-to-high resolution.
  • Next-Generation Sequencing (NGS): Provides definitive, allele-level resolution essential for HSCT.

2. Antibody Screening

• Panel Reactive Antibody (PRA): Estimates the percentage of the general population to which a candidate is sensitized.
• Single Antigen Bead (SAB) Assay (Luminex): High-sensitivity assay detecting circulating Donor-Specific Antibodies (DSAs) against specific HLA alleles.

3. Crossmatching

Determines the presence of pre-existing recipient antibodies against donor cells:

• Complement-Dependent Cytotoxicity (CDC) Crossmatch: Detects complement-fixing IgG/IgM antibodies. A positive CDC crossmatch against donor T-cells is a contraindication to transplantation (predicts hyperacute rejection).
• Flow Cytometry Crossmatch (FCXM): More sensitive than CDC; detects non-complement-fixing low-titer antibodies.
• Virtual Crossmatch: An informatics-based approach comparing donor HLA typing with the recipient’s Luminex-defined antibody profile to predict physical crossmatch outcomes.

Clinical Relevance in Pediatric Transplantation

• Lifelong Immunosuppression Avoidance: Maximizing HLA matching is vital in pediatric recipients to lower cumulative immunosuppressive drug toxicity (renal impairment, growth failure, post-transplant lymphoproliferative disorder - PTLD).
• Highly Sensitized Pediatric Patients: Pediatric patients requiring multiple surgeries or blood transfusions prior to transplantation develop high PRAs. They benefit from desensitization protocols (plasmapheresis, IVIG, Rituximab) and paired donor exchange programs.